Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse ‐free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia
ConclusionsWhile HSCT has historically led to a survival advantage in Ph+ ALL, the results of our study demonstrate that it may have a less beneficial role in the era of newer generation TKIs such as dasatinib.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Jeremy Chang,
Dan Douer,
Ibrahim Aldoss,
Golnaz Vahdani,
Ah ‐Reum Jeong,
Zunera Ghaznavi,
Sherry Zhang,
George Yaghmour,
Kum‐Ja Lee,
Ashley Weissman,
Mojtaba Akhtari Tags: ORIGINAL RESEARCH Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Chemotherapy | Leukemia | Stem Cell Therapy | Stem Cells | Study | Transplants